The Efficacy and Safety of Enarodustat for the Treatment of Anemia in Hemodialysis-Dependent Chronic Kidney Disease Patients: A Phase 3, Multicenter, Randomized, Active-Comparator (Recombinant Human Erythropoietin), Open-Label Study - The ENARODIAL Study.
Haishan Wu, Zhen Ai, Aiying Liu, Hong Ye, Changyou Sun, Aicheng Yang, Wenli Chen, Zhihua Zheng, Caili Wang, Yuehong Li, Ning Cao, Cheng Wang, Yuou Xia, Hong Cheng, Ping Luo, Qiongqiong Yang, Yuehong Yan, Hua Zhou, Nan Mao, Zibo Xiong, Bicheng Liu, Daqing Hong, Qingping Chen, Bo Liang, Qun Luo, Yu Wang, Yongjun Shi, Xiaonong Chen, Li Zhou, Tiekun Yan, Bin Zhu, Jianwen Wang, Menghua Chen, Yongjun Zhu, Tianjun Guan, Song Wang, Shengmei Mu, Yuanyuan Chen, Xiaojuan Lian, Zichen Liu, Yuanwen Xu, Wei Chen
Am J Nephrol 1-12
摘要
摘要
INTRODUCTION: Enarodustat is an oral HIF-PHI for the treatment of chronic kidney disease anemia. METHODS: This phase 3, multicenter, randomized 24-week study assessed enarodustat's noninferiority to rHuEPO for treating hemodialysis-dependent CKD (HD-CKD) anemia. Overall, 100 ESAs-treated patients were randomized 1:1 to enarodustat or rHuEPO for a 24-week treatment with dose adjustment every 4 weeks to maintain hemoglobin (Hb) within target range 100-120 g/L. The primary efficacy endpoint was the between-group difference in mean Hb over weeks 20-24 (evaluation period [noninferiority margin: -10 g/L]). Safety was assessed by treatment-emergent adverse events (TEAEs). RESULTS: Of the 100 patients treated (enarodustat: 50; rHuEPO: 50), 93 completed the study. Demographic and baseline characteristics were comparable. During the evaluation period, the mean Hb level was 106.81 g/L in the enarodustat group and 99.68 g/L in the rHuEPO group. Enarodustat was noninferior to rHuEPO (least squares mean difference: 7.47 g/L [95% confidence interval: 4.17, 10.78]; p < 0.001). The mean Hb level in the enarodustat group remained within the target range throughout the treatment period, with a maintenance rate of 79.6% during weeks 20-24 versus 51.0% for rHuEPO. After switching from ESAs, the enarodustat group showed increased total iron-binding capacity, transferrin, and serum iron, decreased hepcidin by week 4, and increased RET% by week 2. TEAEs incidences were comparable (enarodustat: 90.0%, rHuEPO: 90.0%), with no additional safety concerns for enarodustat. CONCLUSIONS: Enarodustat was noninferior to rHuEPO for the treatment of anemia in HD-CKD patients, with good safety and tolerability over 24 weeks.
KM 提取结果
0 个 Figure · 0 个 KM 面板